$ELOX

Eloxx Pharmaceuticals (NASDAQ:ELOX) received FDA clearance to start a Phase 2 trial for exaluren, a treatment for autosomal dominant polycystic kidney disease (ADPKD). The EXPRESS trial will enroll 60 adults with nonsense mutations, with results expected in 2029. The FDA noted potential for Breakthrough Therapy Designation and accelerated approval. Exaluren has orphan drug designation in the U.S. and Europe. ADPKD affects 160,000-200,000 people in the U.S.

Guggenheim reaffirmed its Buy rating on Eloxx Pharma, setting a $40 price target, suggesting a 200% upside from the recent close. The firm cites strong clinical trial design and experienced leadership as key positives for the company.

Eloxx Pharmaceuticals, Inc. (ELOX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 19, 2026, the Board of Directors (the “Board”) of Eloxx Pharmaceuticals, Inc. (the “Company”) increased the siz

Eloxx Pharmaceuticals completed a 52-week Phase 2 study design for exaluren in 60 ADPKD patients, with dosing expected in 3Q 2027 and results in 1H 2029. The company also appointed T.R. Srinivas, M.D., as Chief Medical Officer. According to Eloxx, a significant and lasting effect on htTKV and supportive eGFR and safety data would be required for accelerated regulatory pathways.

Eloxx Pharmaceuticals (ELOX) appointed Geno Germano, a former Pfizer executive, to its board. Germano has over 35 years of biopharmaceutical experience and currently serves on the boards of Entera Bio and Precision BioSciences. Eloxx is developing treatments for rare kidney diseases, with exaluren as its lead product candidate.

Analysts initiated coverage on several companies: Piper Sandler rated Redwire Corp (RDW) Neutral with a $11 target, Cantor Fitzgerald rated Eloxx Pharmaceuticals (ELOX) Overweight, HC Wainwright rated Sight Sciences (SGHT) Buy with a $14 target, Goldman Sachs rated Anglogold Ashanti (AU) Buy with a $104 target, and Raymond James rated First Financial Bankshares (FFIN) Market Perform.

Eloxx Pharmaceuticals (ELOX) dosed the first two patients in its Phase 2b EXACT study of exaluren for nonsense mutation Alport syndrome. Topline data is expected mid-2027, with a final readout by year-end 2027. The trial aims to evaluate exaluren's safety and efficacy in 24 patients.

Several biotech stocks hit 52-week highs on August 21, 2026. Eloxx (ELOX) rose 16% to $23.40, reporting a Q2 net loss of $4.5M. argenX (ARGX) reached $1,058.69, with positive trial results for VYVGART. Corcept (CORT) hit $123.44, reporting $256M in Q2 revenue. Boundless Bio (BOLD) reached $3.02, initiating a first-in-human trial. Prelude (PRLD) peaked at $6.38, advancing JAK2V617F in Phase 1 trials.

Eloxx Pharmaceuticals (ELOX) rose 20% after FDA cleared its Phase 2b trial for exaluren. Vogenx (VOGX) gained 14% post-IPO. Arcturus (ARCT) advanced 21% on pipeline updates. Zhengye (ZYBT) +7% after Nasdaq compliance. Greenwich (GLSI) +10% on extended lock-up. HeartSciences (HSCS) +8% after $1M investment. AC Immune (ACIU) +8% on Phase 1 data.

Eloxx Pharmaceuticals reported a wider Q2 2026 loss of $4.5M, up from $1.9M a year ago, due to higher R&D and G&A expenses. The company raised $58.3M in a public offering and uplisted to Nasdaq. Eloxx plans to start a Phase 2b trial for exaluren in Q3 2026, with data expected in 2027. The stock is up 18.10% to $21.31.